Incretin‐based therapies, such as the injectable glucagon‐like peptide‐1 (GLP‐1) receptor
agonists and orally administered dipeptidyl peptidase‐4 (DPP‐4) inhibitors, have recently …

The regulation of energy and glucose balance contributes to whole-body metabolic
homeostasis, and such metabolic regulation is disrupted in obesity and diabetes. Metabolic …

The actions of the structurally related proglucagon-derived peptides (PGDPs)—glucagon,
glucagon-like peptide (GLP)-1 and GLP-2—are focused on complementary aspects of …

Satiation for food comprises the physiological processes that result in the termination of
eating. Satiation is evoked by physical and chemical qualities of ingested food, which trigger …

We previously reported that afferent signals of the rat hepatic vagus increased upon
intraportal appearance of insulinotropic hormone glucagon-like peptide-1 (7-36) amide …

This review describes major factors that, singly or together, influence the concentration and
distribution ofd-glucose in mammals, particularly in humans, with emphasis on rest, physical …

Abstract Context: Glucagon-like peptide-1 (GLP-1) 7-36 amide, an insulinotropic hormone
released from the intestinal L cells in response to nutrient ingestion, has been extensively …

There is a growing worldwide epidemic of obesity. Obese people have a higher incidence of
type 2 diabetes and cardiovascular disease, and hence present increasing social, financial …

Known treatments of type 2 diabetes mellitus have limitations such as weight gain, and
hypoglycaemias. A new perspective is the use of incretin hormones and incretin enhancers …

Food intake and energy expenditure are key regulators of body weight. To regulate food
intake, the brain must integrate physiological signals and hedonic cues. The brain plays an …